Source: Insightcare By Harsha Rajasimha, PhD, Founder and CEO, Jeeva Clinical Trials Inc. www.jeevatrials.com To say that COVID-19 has been a challenge to healthcare systems
The COVID-19 pandemic brought a new sense of appreciation for clinical trials as masses watched clinical trials closely while pharmaceutical companies raced against the clock
The growing use of decentralized clinical trials has raised serious concerns regarding verification of patient comprehension and proper informed consent. The solution, says Dr. Harsha
Source: HR.com Serious inefficiencies are hampering clinical trials of new drugs and treatments, prolonging the suffering of millions. Today’s platform technologies, says Dr. Harsha Rajasimha
Source: Pharmaceutical Outsourcing The outbreak of the COVID-19 pandemic seriously disrupted new drug testing, treatments, and in-person healthcare services; access to clinical trial sites was
Source: Outsourcing-Pharma Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies. According to Harsha
Serious inefficiencies are hampering clinical trials of new drugs and treatments, prolonging the suffering of millions. Today’s platform technologies, says Dr. Harsha Rajasimha of Jeeva
Traditional clinical guidelines, and stand-alone patient study and care pathways are proven to be increasingly inadequate, especially in a post-pandemic world with low clinical adherence,
Source: Byrdie Before medications and treatments can be deemed safe and effective for the masses, they are rigorously studied in a process called clinical trials.
Disparities related to diversity, equity, and inclusion (DEI) are common and well-known in clinical trials. It is well-documented that racial minorities, underprivileged, and non-white ethnic
Jeeva Clinical Trials Inc.
